Illumina (NASDAQ:ILMN) Price Target Raised to $145.00 at UBS Group

Illumina (NASDAQ:ILMN) had its price target increased by UBS Group from $133.00 to $145.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a neutral rating on the life sciences company’s stock.

Other equities analysts have also recently issued research reports about the stock. Citigroup boosted their price target on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday. Robert W. Baird increased their target price on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average price target of $161.50.

Illumina Trading Up 1.0 %

Shares of Illumina stock opened at $154.96 on Tuesday. The company’s 50-day moving average price is $136.87 and its 200-day moving average price is $122.92. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina has a 12-month low of $89.00 and a 12-month high of $156.66. The company has a market cap of $24.69 billion, a price-to-earnings ratio of -15.56 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the company posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities analysts expect that Illumina will post 3.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA lifted its stake in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after purchasing an additional 1,997,010 shares during the period. Millennium Management LLC boosted its stake in shares of Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after acquiring an additional 1,118,747 shares during the last quarter. Capital World Investors grew its position in shares of Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after acquiring an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in shares of Illumina in the 2nd quarter worth $77,628,000. Finally, Swedbank AB bought a new position in Illumina in the 1st quarter worth $99,682,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.